Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

PMGC Holdings Inc. ELAB NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
35/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

PMGC Holdings Inc. (ELAB) is a Biotechnology company in the Healthcare sector, currently trading at $4.20. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: ELAB trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).

Financials: revenue is $590,084, +30.5%/yr average growth. Net profit margin is 0% (thin). Gross margin is 31.4% (-26.3 pp trend).

Balance sheet: total debt is $3M against $8M equity (Debt-to-Equity (D/E) ratio 0.34, conservative). Current ratio is 1.74 (strong liquidity). Debt-to-assets is 20.6%. Total assets: $13M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 21/100 (Fail), Future ?/100 (Fail), Income 30/100 (Fail).

ELAB SharesGrow Score Overview

44/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ELAB

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
ELAB: +30.5%/yr revenue is, -28%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ELAB: Debt-to-Equity (D/E) ratio 0.34 (conservative), Current ratio is 1.74 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
ELAB: Gross margin is 31.4% (-26.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
30/100
ELAB: Net profit margin is 0%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.62-467.3684
Volume2.16M
Avg Volume (30D)7.33M
Market Cap$8.13M
Beta (1Y)1.12
Share Statistics
Shares Outstanding$20.35K
IPO Date2023-11-21
Employees2
CEOGraydon Bensler
Financial Highlights & Ratios
Revenue (TTM)$590.08K
Gross Profit$185.31K
EBITDA$-7.68M
Operating Income$-7.78M
Total Cash$5.4M
Total Debt$2.64M
Net Debt$-2.76M
Total Assets$12.87M
Price / Sales (P/S)13.79
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS73017P5089

Price Chart

Track all markets on TradingView
ELAB
PMGC Holdings Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.62 52WK RANGE 467.37

People Also View

NKGN
NKGN
NKGen Biotech, Inc. Common Stock
$0.06
+166.67%
 MLEC
MLEC
Moolec Science S.A.
$7.41
-6.68%
 ATXI
ATXI
Avenue Therapeutics, Inc.
$0.51
+14.17%
 NCEL
NCEL
NewcelX Ltd.
$2.50
-0.79%
 DRMA
DRMA
Dermata Therapeutics, Inc.
$1.26
+0.80%
 VRAX
VRAX
Virax Biolabs Group Limited
$0.15
+1.15%
 XRTX
XRTX
XORTX Therapeutics Inc.
$2.16
-0.46%
 WINT
WINT
Windtree Therapeutics, Inc.
$0.01
+11.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message